Navigation Links
New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Date:4/9/2008

Emerging Agent GlaxoSmithKline's Rezonic Demonstrating Efficacy for Delayed Chemotherapy-Induced Nausea and Vomiting, According to a New Report from

Decision Resources

WALTHAM, Mass., April 9, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the regimen of Merck's Emend for Injection/Ivemend combined with 5-HT3 RA, is positioned to earn gold-standard status in the treatment of chemotherapy-induced nausea and vomiting by 2011. The regimen of Emend for Injection/Ivemend and 5-HT3 RA offers robust efficacy and key advantages in delivery as a result of its availability in a single-dose IV formulation that is more convenient than the three-consecutive-day-dosing schedule of Merck's Emend, the current gold standard.

The new report entitled Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents, also finds that GlaxoSmithKline's Rezonic, launching in 2009 as the second-to-market NK1 RA, is positioned as the only emerging agent, compared with Emend, with the potential to demonstrate better control over delayed chemotherapy-induced nausea and vomiting in patients taking highly emetogenic chemotherapy. Preliminary data from clinical trials show that the addition of oral Rezonic to GlaxoSmithKline's Zofran and Merck/Banyu's Decadron result in an 86 percent of patients with no emetic episodes and do not require rescue therapy compared with Emend's 68 percent; however, more data is needed to confirm the effect on delayed chemotherapy-induced nausea and vomiting. Additionally, unless Rezonic shows extraordinary efficacy or is priced much lower than currently available NK1 antagonists, it is not expected to gain more patient share than the Emend franchise owing to Emend's first-to-market status in the injectable NK1 antagonist class.

<
'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Navitas, a leading Regulatory Service provider, today announced that ... in Bogota, Colombia . Navitas, expansion into ... by Colombia , the third largest economy in ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... clients to communicate with Navitas regulatory professionals in close to or the ...
(Date:7/3/2015)... Texas (PRWEB) , ... July ... ... biotechnology company providing industry-leading products for use in applications such as animal ... in wastewater treatment plants and restaurant kitchen settings, announced today that it ...
(Date:7/3/2015)... , ... July 03, 2015 , ... The global failure ... 7.52% from 2015 to 2020. The bioscience market is expected to grow at the ... use of failure analysis equipment in the research labs and academic institutions for root ...
(Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
Breaking Biology Technology:Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3DryLet to Highlight Benefits of Patented ManureMagicâ„¢ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... Aug. 20 GSI Group Inc.,(Nasdaq: GSIG ) ... the tender offer by its indirect wholly-owned subsidiary Eagle,Acquisition ... of,Excel Technology, Inc. (Nasdaq: XLTC ). The initial ... City time, on Tuesday, August 19,2008., The depositary ...
... Strategic Fit with Lilly,s Animal Health Division, GREENFIELD, ... and Company (NYSE: LLY ), today announced that ... to the dairy cow supplement,Posilac(R) (sometribove), as well as ... )., "Global dairy demand is increasing, outstripping supply, ...
... has selected OpenClinica as its electronic data capture (EDC) and ... , ... Ruetlingen, Germany (PRWEB) August ... has selected OpenClinica as its http://www.openclinica.org/section.php?sid=1 [electronic data ...
Cached Biology Technology:GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 2GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 3Elanco Announces Acquisition of Posilac(R) Dairy Business 2Elanco Announces Acquisition of Posilac(R) Dairy Business 3OpenClinica EDC Solution Deployed for Retina Implant Studies 2OpenClinica EDC Solution Deployed for Retina Implant Studies 3
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
(Date:6/15/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... announces that its leading payment security technology, the Wocket® smart ... NYC June 18th. Digital Experience! @ NYC is ... to over 300 of the top media covering the sector. ... New York City from 6:00 to ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... 2012 In a study published in the March ... Academy of Child and Adolescent Psychiatry , Katherine Rice ... of Atlanta, and Emory University School of Medicine, used ... social disability in children with autism spectrum disorders (ASD) ...
... team of researchers show that most neandertals in Europe died ... a Europe populated by a stable neandertal population for hundreds ... therefore be revised. This new perspective on the ... in Molecular Biology and Evolution . The results indicate ...
... PHOENIX, Ariz. Feb. 27, 2012 The 9th ... pancreatic cancer research at the Translational Genomics Research Institute ... will go toward new international clinical trials run by ... first time that major retailers, producers and suppliers in ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2European Neandertals were on the verge of extinction even before the arrival of modern humans 2Celebrity Golf Classic raises $553,443 for Seena Magowitz Foundation 2
SDS-OutT SDS Precipitation Reagent...
... Sciclone inL10 Workstation from Caliper represents a ... for the first time the ability to ... react to changing conditions. In addition, ... viscosity due to changes in temperature, and ...
... The Staccato Series of systems ... for today's drug discovery, genomics, proteomics ... are available in three base configurations; ... Custom Systems Series. All Staccato ...
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
Biology Products: